<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01707407</url>
  </required_header>
  <id_info>
    <org_study_id>CC-4047-CP-008</org_study_id>
    <nct_id>NCT01707407</nct_id>
  </id_info>
  <brief_title>A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects</brief_title>
  <acronym>DDI</acronym>
  <official_title>A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To evaluate the pharmacokinetics (PK) of pomalidomide administered with the CYP3A4/P-gp&#xD;
           inhibitor ketoconazole compared with pomalidomide alone in healthy male subjects.&#xD;
&#xD;
        2. To evaluate the PK of pomalidomide administered with the CYP3A4/P-gp inhibitor&#xD;
           ketoconazole plus the CYP1A2 inhibitor fluvoxamine compared with pomalidomide alone in&#xD;
           healthy male subjects.&#xD;
&#xD;
        3. To assess the PK of pomalidomide administered with the CYP1A2 inhibitor fluvoxamine and&#xD;
           the CYP3A4/P-gp inhibitor ketoconazole compared with pomalidomide plus the CYP3A4/P-gp&#xD;
           inhibitor ketoconazole in healthy male subjects.&#xD;
&#xD;
      Part 2&#xD;
&#xD;
      1) To evaluate the pharmacokinetics of pomalidomide administered with the CYP3A4 inducer&#xD;
      carbamazepine compared with pomalidomide alone in healthy male volunteers.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
      1) To evaluate the safety of pomalidomide in Part 1 and Part 2 when administered with&#xD;
      ketoconazole, fluvoxamine and/or carbamazepine.&#xD;
&#xD;
      In addition: To evaluate the safety of pomalidomide in Part 1 and Part 2 when administered&#xD;
      with ketoconazole, fluvoxamine and/or carbamazepine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single-center, open label non randomized, 2-part study with 3 periods in Part&#xD;
      1, and 2 periods in Part 2. Parts 1 and 2 will be conducted in parallel. The entire study&#xD;
      will consist of a screening phase, two dosing parts, and a follow-up telephone call for&#xD;
      safety. All Periods will be separated by a washout period of at least 3 days (no more than 5&#xD;
      days) from the last pomalidomide dose to the next drug dose.&#xD;
&#xD;
      Safety will be monitored throughout the study. Safety evaluations will include adverse event&#xD;
      (AE) reporting, concomitant medications, PEs, vital sign measurements, 12-lead ECGs, and&#xD;
      clinical laboratory safety tests.&#xD;
&#xD;
      Thirty-two healthy (16 per each Part), male adult subjects 18 to 55 years of age who meet all&#xD;
      inclusion criteria and do not meet any of the exclusion criteria will be enrolled in the&#xD;
      study. Subjects enrolled in Part 1 cannot participate in Part 2 and vice versa.&#xD;
&#xD;
      Study treatments (pomalidomide, ketoconazole, fluvoxamine and carbamazepine) should be&#xD;
      administered with meals and subjects should be a served a standard meal (ie, breakfast or&#xD;
      dinner) approximately 30 minutes prior to dosing. The meal should be consumed within 30&#xD;
      minutes from serving and dosing must occur 30 minutes (±5 minutes) after serving the meal.&#xD;
      Subjects should be encouraged to consume the whole meal served prior to dosing. After each&#xD;
      dosing, food and beverages (except water) will be withheld from all subjects until at least 4&#xD;
      hours post dose; thereafter, subjects will be served standard meals and snacks.&#xD;
&#xD;
      For determination of plasma concentrations of pomalidomide, ketoconazole, fluvoxamine and&#xD;
      carbamazepine (and its active metabolite carbamazepine 10,11-epoxide) in each dosing regimen&#xD;
      (Period), serial blood samples will be collected.&#xD;
&#xD;
      A safety follow-up will be conducted by telephone within 4 to 7 days from the last dose. In&#xD;
      the event a subject discontinues from the study prematurely, an early termination visit will&#xD;
      be performed within 4 days following the day of discontinuation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2012</start_date>
  <completion_date type="Actual">November 1, 2012</completion_date>
  <primary_completion_date type="Actual">November 1, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK-Cmax</measure>
    <time_frame>Up to 13 days</time_frame>
    <description>Cmax-Maximum observed concentration in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-Tmax</measure>
    <time_frame>Up to 13 days</time_frame>
    <description>Tmax: Time to maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-AUC</measure>
    <time_frame>Up to 13 days</time_frame>
    <description>AUC-Area under the plasma concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-(T1/2)</measure>
    <time_frame>Up to 13 days</time_frame>
    <description>T1/2-Terminal half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-CL/F</measure>
    <time_frame>Up to 13 days</time_frame>
    <description>CL/F-Apparent total plasma clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-Vz/F</measure>
    <time_frame>Up to 13 days</time_frame>
    <description>Vz/F: Apparent total volume of distribution</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Pharmacology, Clinical</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Pomalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pomalidomide plus Ketoconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pomalidomide plus Ketoconazole plus Fluvoxamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pomalidomide plus Carbamazepine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>4 mg pomalidomide capsule administered orally once in the morning</description>
    <arm_group_label>Pomalidomide</arm_group_label>
    <arm_group_label>Pomalidomide plus Carbamazepine</arm_group_label>
    <arm_group_label>Pomalidomide plus Ketoconazole</arm_group_label>
    <arm_group_label>Pomalidomide plus Ketoconazole plus Fluvoxamine</arm_group_label>
    <other_name>(CC-4047)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>200 mg Ketoconazole tablet administered orally twice a day on Days 1-7.</description>
    <arm_group_label>Pomalidomide plus Ketoconazole</arm_group_label>
    <arm_group_label>Pomalidomide plus Ketoconazole plus Fluvoxamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvoxamine</intervention_name>
    <description>50 mg Fluvoxamine tablet administered orally twice a day on Days 1-7.</description>
    <arm_group_label>Pomalidomide plus Ketoconazole plus Fluvoxamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbamazepine</intervention_name>
    <description>100 mg Carbamazepine tablet administered orally once in the evening on Day 1&#xD;
100 mg Carbamazepine tablet administered orally twice daily on Days 2-3&#xD;
200 mg Carbamazepine tablet administered orally twice daily on Days 4-11</description>
    <arm_group_label>Pomalidomide plus Carbamazepine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Must understand and voluntarily sign a written informed consent document (ICD) prior&#xD;
             to any study-related procedures being performed.&#xD;
&#xD;
          -  Must be able to communicate with the investigator, understand and comply with the&#xD;
             requirements of the study, and agree to adhere to restrictions and examination&#xD;
             schedules.&#xD;
&#xD;
          -  Must be a male 18 to 55 years of age (inclusive) at the time of signing the ICD, with&#xD;
             a body mass index (BMI = weight [kg]/(height [m2]) between 18 and 33 kg/m2 (inclusive)&#xD;
             and weight between 60 and 100 kg (132 to 220 lbs; inclusive)&#xD;
&#xD;
               1. For Part 1, subjects may be of any race.&#xD;
&#xD;
               2. For Part 2, subjects must be non-Asian or non-Asian descent.&#xD;
&#xD;
          -  Must be healthy (at Screening and Day -1 of Period 1) as determined by the&#xD;
             investigator on the basis of medical history, physical examination, clinical&#xD;
             laboratory safety test results, vital signs, and 12 lead electrocardiograms (ECGs).&#xD;
&#xD;
               1. Vital signs (systolic and diastolic blood pressure, pulse rate, and oral body&#xD;
                  temperature) will be assessed in the supine position after the subject has rested&#xD;
                  for at least 5 minutes.&#xD;
&#xD;
               2. Subject must be afebrile (febrile is defined as ≥ 38.5ºC or 101.3 Fahrenheit).&#xD;
&#xD;
               3. Systolic blood pressure in the range of 90 to 140 mmHg, diastolic blood pressure&#xD;
                  in the range of 60 to 90 mmHg, and pulse rate in the range of 45 to 100 bpm.&#xD;
&#xD;
               4. Must have a normal or clinically acceptable 12-lead ECG, with a QTcF value ≤ 430&#xD;
                  msec.&#xD;
&#xD;
               5. Clinical laboratory safety tests must be within normal limits or clinically&#xD;
                  acceptable to the Principal investigator (PI)&#xD;
&#xD;
          -  Subjects (with or without vasectomy) must agree to use barrier contraception (ie,&#xD;
             latex condom or any non-latex condom not made out of natural [animal] membrane [eg,&#xD;
             polyurethane]) and one other method (eg, spermicide) when engaging in sexual activity&#xD;
             with woman of child-bearing potential during study conduct, and for 90 days after the&#xD;
             last dose of study medication.&#xD;
&#xD;
          -  Must agree to refrain from donating blood or plasma (other than for this study) while&#xD;
             participating in this study and for at least 28 days after the last dose of study&#xD;
             drug.&#xD;
&#xD;
          -  Similarly, must agree to refrain from donating sperm while participating in this study&#xD;
             and for at least 90 days after the last dose of study drug.&#xD;
&#xD;
          -  Will be counseled about pregnancy precautions and risks of fetal exposure and agree to&#xD;
             comply with the conditions described in the counseling document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any clinically significant and relevant neurological, gastrointestinal,&#xD;
             renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine,&#xD;
             hematological, allergic disease, drug allergies, known hypersensitivity to a member of&#xD;
             the class of-IMIDs (immune-mediated inflammatory diseases), or other major disorders&#xD;
&#xD;
          -  Any significant medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from participating in the study.&#xD;
&#xD;
          -  Any condition including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he were to participate in the study.&#xD;
&#xD;
          -  Any condition that confounds the ability to interpret data from the study.&#xD;
&#xD;
          -  Used any prescribed systemic or topical medication within 30 days of the first dose&#xD;
             administration, unless Sponsor agreement is obtained.&#xD;
&#xD;
          -  Used any non-prescribed systemic or topical medication (including vitamin/mineral&#xD;
             supplements, and herbal medicines) within 14 days of the first dose administration,&#xD;
             unless Sponsor agreement is obtained.&#xD;
&#xD;
          -  Has any surgical or medical conditions possibly affecting drug absorption,&#xD;
             distribution, metabolism and excretion (ADME), eg, bariatric procedure.&#xD;
&#xD;
          -  Donated blood or plasma within 8 weeks before the first dose administration to a blood&#xD;
             bank or blood donation center.&#xD;
&#xD;
          -  History of drug abuse (as defined by the current version of the Diagnostic and&#xD;
             Statistical Manual within 2 years before dosing, or positive drug screening test&#xD;
             reflecting consumption of illicit drugs.&#xD;
&#xD;
          -  History of alcohol abuse (as defined by the current version of the DSM) within 2 years&#xD;
             before dosing, or positive alcohol screen.&#xD;
&#xD;
          -  Known to have, or tests positive for, active or chronic hepatitis B, hepatitis C, or&#xD;
             HIV antibodies.&#xD;
&#xD;
          -  Exposed to an investigational drug (new chemical entity) within 60 days preceding the&#xD;
             first dose administration, or 5 half-lives of that investigational drug, if known&#xD;
             (whichever is longer).&#xD;
&#xD;
          -  Received vaccination (excluding seasonal flu vaccination) within 90 days of the study&#xD;
             drug administration.&#xD;
&#xD;
          -  Smokes more than 10 cigarettes, or consumes the equivalent in tobacco, per day.&#xD;
&#xD;
          -  Subjects who are part of the staff personnel or family members of the investigational&#xD;
             study staff.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Palmisano, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Research Unit, Inc</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff D, O'Neill B, Pulido J, Jaeckle KA, Grommes C, Witzig TE. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018 Nov 22;132(21):2240-2248. doi: 10.1182/blood-2018-02-835496. Epub 2018 Sep 27.</citation>
    <PMID>30262659</PMID>
  </reference>
  <reference>
    <citation>Mark TM, Forsberg PA, Rossi AC, Pearse RN, Pekle KA, Perry A, Boyer A, Tegnestam L, Jayabalan D, Coleman M, Niesvizky R. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. Blood Adv. 2019 Feb 26;3(4):603-611. doi: 10.1182/bloodadvances.2018028027.</citation>
    <PMID>30792190</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 12, 2012</study_first_submitted>
  <study_first_submitted_qc>October 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2012</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CC-4047</keyword>
  <keyword>Pomalidomide</keyword>
  <keyword>Ketoconazole</keyword>
  <keyword>Fluvoxamine</keyword>
  <keyword>Carbamazepine</keyword>
  <keyword>DDI</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Carbamazepine</mesh_term>
    <mesh_term>Fluvoxamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01707407
org study id: CC-4047-CP-008
nct id: NCT01707407
lead sponsor: 
has dmc: No
1. To evaluate the pharmacokinetics (PK) of pomalidomide administered with the CYP3A4/P-gp
           inhibitor ketoconazole compared with pomalidomide alone in healthy male subjects.

        2. To evaluate the PK of pomalidomide administered with the CYP3A4/P-gp inhibitor
           ketoconazole plus the CYP1A2 inhibitor fluvoxamine compared with pomalidomide alone in
           healthy male subjects.

        3. To assess the PK of pomalidomide administered with the CYP1A2 inhibitor fluvoxamine and
           the CYP3A4/P-gp inhibitor ketoconazole compared with pomalidomide plus the CYP3A4/P-gp
           inhibitor ketoconazole in healthy male subjects.

      Part 2

      1) To evaluate the pharmacokinetics of pomalidomide administered with the CYP3A4 inducer
      carbamazepine compared with pomalidomide alone in healthy male volunteers.

      Secondary Objectives

      1) To evaluate the safety of pomalidomide in Part 1 and Part 2 when administered with
      ketoconazole, fluvoxamine and/or carbamazepine.

      In addition: To evaluate the safety of pomalidomide in Part 1 and Part 2 when administered
      with ketoconazole, fluvoxamine and/or carbamazepine.
This will be a single-center, open label non randomized, 2-part study with 3 periods in Part
      1, and 2 periods in Part 2. Parts 1 and 2 will be conducted in parallel. The entire study
      will consist of a screening phase, two dosing parts, and a follow-up telephone call for
      safety. All Periods will be separated by a washout period of at least 3 days (no more than 5
      days) from the last pomalidomide dose to the next drug dose.

      Safety will be monitored throughout the study. Safety evaluations will include adverse event
      (AE) reporting, concomitant medications, PEs, vital sign measurements, 12-lead ECGs, and
      clinical laboratory safety tests.

      Thirty-two healthy (16 per each Part), male adult subjects 18 to 55 years of age who meet all
      inclusion criteria and do not meet any of the exclusion criteria will be enrolled in the
      study. Subjects enrolled in Part 1 cannot participate in Part 2 and vice versa.

      Study treatments (pomalidomide, ketoconazole, fluvoxamine and carbamazepine) should be
      administered with meals and subjects should be a served a standard meal (ie, breakfast or
      dinner) approximately 30 minutes prior to dosing. The meal should be consumed within 30
      minutes from serving and dosing must occur 30 minutes (±5 minutes) after serving the meal.
      Subjects should be encouraged to consume the whole meal served prior to dosing. After each
      dosing, food and beverages (except water) will be withheld from all subjects until at least 4
      hours post dose; thereafter, subjects will be served standard meals and snacks.

      For determination of plasma concentrations of pomalidomide, ketoconazole, fluvoxamine and
      carbamazepine (and its active metabolite carbamazepine 10,11-epoxide) in each dosing regimen
      (Period), serial blood samples will be collected.

      A safety follow-up will be conducted by telephone within 4 to 7 days from the last dose. In
      the event a subject discontinues from the study prematurely, an early termination visit will
      be performed within 4 days following the day of discontinuation.
allocation: Non-Randomized
intervention model: Parallel Assignment
primary purpose: Other
masking: None (Open Label)
measure: PK-Cmax
time frame: Up to 13 days
description: Cmax-Maximum observed concentration in plasma
measure: PK-Tmax
time frame: Up to 13 days
description: Tmax: Time to maximum concentration
measure: PK-AUC
time frame: Up to 13 days
description: AUC-Area under the plasma concentration-time curve
measure: PK-(T1/2)
time frame: Up to 13 days
description: T1/2-Terminal half-life
measure: PK-CL/F
time frame: Up to 13 days
description: CL/F-Apparent total plasma clearance
measure: PK-Vz/F
time frame: Up to 13 days
description: Vz/F: Apparent total volume of distribution
measure: Adverse Events
time frame: Up to 15 days
description: Number of participants with adverse events
arm group label: Pomalidomide
arm group type: Experimental
arm group label: Pomalidomide plus Ketoconazole
arm group type: Experimental
arm group label: Pomalidomide plus Ketoconazole plus Fluvoxamine
arm group type: Experimental
arm group label: Pomalidomide plus Carbamazepine
arm group type: Experimental
intervention type: Drug
intervention name: Pomalidomide
description: 4 mg pomalidomide capsule administered orally once in the morning
arm group label: Pomalidomide
arm group label: Pomalidomide plus Carbamazepine
arm group label: Pomalidomide plus Ketoconazole
arm group label: Pomalidomide plus Ketoconazole plus Fluvoxamine
other name: (CC-4047)
intervention type: Drug
intervention name: Ketoconazole
description: 200 mg Ketoconazole tablet administered orally twice a day on Days 1-7.
arm group label: Pomalidomide plus Ketoconazole
arm group label: Pomalidomide plus Ketoconazole plus Fluvoxamine
intervention type: Drug
intervention name: Fluvoxamine
description: 50 mg Fluvoxamine tablet administered orally twice a day on Days 1-7.
arm group label: Pomalidomide plus Ketoconazole plus Fluvoxamine
intervention type: Drug
intervention name: Carbamazepine
description: 100 mg Carbamazepine tablet administered orally once in the evening on Day 1
100 mg Carbamazepine tablet administered orally twice daily on Days 2-3
200 mg Carbamazepine tablet administered orally twice daily on Days 4-11
arm group label: Pomalidomide plus Carbamazepine
criteria: 
gender: Male
minimum age: 18 Years
maximum age: 55 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Maria Palmisano, MD
role: Study Director
affiliation: Celgene Corporation
facility: 
country: United States
citation: Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff D, O'Neill B, Pulido J, Jaeckle KA, Grommes C, Witzig TE. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018 Nov 22;132(21):2240-2248. doi: 10.1182/blood-2018-02-835496. Epub 2018 Sep 27.
PMID: 30262659
citation: Mark TM, Forsberg PA, Rossi AC, Pearse RN, Pekle KA, Perry A, Boyer A, Tegnestam L, Jayabalan D, Coleman M, Niesvizky R. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. Blood Adv. 2019 Feb 26;3(4):603-611. doi: 10.1182/bloodadvances.2018028027.
PMID: 30792190
responsible party type: Sponsor
mesh term: Ketoconazole
mesh term: Pomalidomide
mesh term: Carbamazepine
mesh term: Fluvoxamine